Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Stock Information | RedChip

Citius Pharmaceuticals Inc. (NASDAQ: CTXR) Listen to this Section


$0.60
+0.0185 ( +3.16% ) 1.1M

Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: LYMPHIR for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma . Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome.

Market Data


Open


$0.60

Previous close


$0.59

Volume


1.1M

Market cap


$109.00M

Day range


$0.59 - $0.62

52 week range


$0.48 - $1.07

Insider Ownership Transactions

Total Amount Purchased: -550,000.00 | $ -332,640.00

Date Type Amount Purchased Purchaser
2023-10-12 Sale -550000.00 Mazur Leonard L

SEC Fillings


Form Type Description Pages Date
4 Insider transactions 1 Mar 18, 2024
8-k 8K-related 15 Mar 18, 2024
3 Insider transactions 2 Mar 18, 2024
8-k 8K-related 14 Mar 13, 2024
8-k 8K-related 16 Feb 15, 2024
10-q Quarterly Reports 53 Feb 14, 2024
8-k 8K-related 16 Feb 14, 2024
ars Annual reports 1 Jan 26, 2024
def Proxies and info statements 4 Jan 26, 2024
8-k 8K-related 14 Jan 23, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.